WMWeiwei Mu

Weiwei Mu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Weiwei Mu has a total of 72 co-authors. Here are the top co-authors by number of shared publications:

  • Na Zhang

    Cheeloo College of Medicine, Shandong University 44 Wenhua Culture Road

    10 shared publications
  • Yongjun Liu

    Cheeloo College of Medicine, Shandong University 44 Wenhua Culture Road

    8 shared publications
  • Shuang Liang

    NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China

    5 shared publications
  • Tong Gao

    NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China

    5 shared publications
  • Shunli Fu

    NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China

    4 shared publications
  • Zipeng Zhang

    Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China

    4 shared publications

Latest Publications

  • Bone Marrow-Targeted Nano-delivery Systems for Refractory Hematologic Malignancies: From Delivery Barriers to Clinical Translation

    by Ruixin Li, Jie Liu, Xiaohui Kong, Jinhu Liu, Jia Gao, Weiwei Mu, Na Zhang, Yongjun Liu

    Hematologic malignancies (HMs) pose a serious threat to human health and are associated with a high metastatic rate and poor prognosis. The strong tumor heterogeneity, marked therapeutic resistance, poor targeting of conventional therapies, and toxic side effects make them a major challenge in the clinical treatment of HMs. As the principal site of hematopoiesis and immune cell production, the bone marrow (BM) is a critical site in the treatment of HMs. However, low blood perfusion and the complexity of the microenvironment severely hinder drug accumulation within the BM, which is also the core bottleneck in the treatment of HMs. Owing to their unique physicochemical properties, nano-delivery systems enable efficient BM-targeted delivery, providing effective strategies to overcome this therapeutic bottleneck. This review discusses the structure of the BM and the mechanisms of delivery barriers, systematically analyzes the design advances of BM-targeted nano-delivery systems, highlights different delivery strategies, and addresses key issues in the clinical translation of nano-delivery systems, including biosafety, manufacturing, and regulation of in vivo delivery efficiency. It also outlines future directions, establishing a BM-targeted delivery framework to advance the treatment of HMs and providing a theoretical reference for the development and clinical application of BM-targeted nano-delivery systems, thereby facilitating breakthroughs in precision therapy for HMs.

  • Multivalent Antibody-Recruiters Targeting Fibroblast Activation Protein for Innate Immune Killing

    by Weiwei Mu, Yong Chen, Zifu Zhong, Jamie De Baere, Heleen Lauwers, Demi Defreyne, Haixia Peng, Bruno G. De Geest, Benoit Louage

    Fibroblast activation protein (FAP) is selectively overexpressed on cancer-associated fibroblasts (CAFs), making it a prime target for reshaping the tumor microenvironment. Antibody-recruiting molecules (ARMs) offer a monoclonal antibody alternative by enabling endogenous antibodies binding to eliminate target cells. Here, we report the development of multivalent FAP-targeting ARMs based on a truncated derivative of the high-affinity small-molecule OncoFAP. Initial attempts to generate monovalent ARMs by conjugating the FAPL to dinitrophenol (DNP) failed to enable antibody recruitment, despite efficient ligand binding. To overcome steric limitations, FAPL and DNP were coconjugated onto a 150 kDa dextran scaffold for multivalent display of FAP and antibody binding motifs. These dextran-based ARMs efficiently recruited anti-DNP antibodies, triggered robust complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP) of FAP-expressing cells in vitro. Our findings demonstrate that multivalent macromolecular scaffolds effectively enable small-molecule-mediated antibody recruitment to noninternalizing targets like FAP, highlighting their potential for therapeutic tumor stroma remodeling.


  • Open Access

    Glypican-3-targeted macrophages delivering drug-loaded exosomes offer efficient cytotherapy in mouse models of solid tumours

    by Jinhu Liu, Huajun Zhao, Tong Gao, Xinyan Huang, Shujun Liu, Meichen Liu, Weiwei Mu, Shuang Liang, Shunli Fu, Shijun Yuan, et al.

    Cytotherapy is a strategy to deliver modified cells to a diseased tissue, but targeting solid tumours remains challenging. Here we design macrophages, harbouring a surface glypican-3-targeting peptide and carrying a cargo to combat solid tumours. The anchored targeting peptide facilitates tumour cell recognition by the engineered macrophages, thus enhancing specific targeting and phagocytosis of tumour cells expressing glypican-3. These macrophages carry a cargo of the TLR7/TLR8 agonist R848 and INCB024360, a selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, wrapped in C16-ceramide-fused outer membrane vesicles (OMV) of Escherichia coli origin (RILO). The OMVs facilitate internalization through caveolin-mediated endocytosis, and to maintain a suitable nanostructure, C16-ceramide induces membrane invagination and exosome generation, leading to the release of cargo-packed RILOs through exosomes. RILO-loaded macrophages exert therapeutic efficacy in mice bearing H22 hepatocellular carcinomas, which express high levels of glypican-3. Overall, we lay down the proof of principle for a cytotherapeutic strategy to target solid tumours and could complement conventional treatment.


  • Open Access

    Localized light-triggered release macrophage cytopharmaceuticals containing O-nitrobenzyl group for enhanced solid tumor cell-chemotherapy

    by Jinhu Liu, Han Yang, Xiao Sang, Tong Gao, Zipeng Zhang, Shunli Fu, Huizhen Yang, Lili Chang, Xiaoqing Liu, Shuang Liang, et al.


  • Open Access

    CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma

    by Jinhu Liu, Weiwei Mu, Tong Gao, Yuxiao Fang, Na Zhang, Yongjun Liu

    Liver cancer, especially hepatocellular carcinoma, is an important cause of cancer-related death, and its incidence is increasing worldwide. Nano drug delivery systems have shown great promise in the treatment of cancers. In order to improve their therapeutic efficacy, it is very important to realize the high accumulation and effective release of drugs at the tumor site. In this manuscript, using doxorubicin (DOX) as a model drug, CD13-targeted mesoporous silica nanoparticles coated with NGR-peptide-modified pegylated carboxymethyl chitosan were constructed (DOX/MSN-CPN). DOX/MSN-CPN comprises a spherical shape with an obvious capping structure and a particle size of 125.01 ± 1.52 nm. With a decrease in pH, DOX/MSN-CPN showed responsive desorption from DOX/MSN-CPN and pH-responsive release of DOX was observed. Meanwhile, DOX/MSN-CPN could be efficiently absorbed through NGR-mediated internalization in vitro and could efficiently deliver DOX to tumor tissues with long accumulation times in vivo, suggesting good active targeting properties. Moreover, significant tumor inhibition has been observed in antitumor studies in vivo. This study provides a strategy of utilizing DOX/MSN-CPN as a nano-platform for drug delivery, which has superb therapeutic efficacy and safety for the treatment of hepatocellular carcinoma both in vivo and in vitro.


  • In-situ self-assembled vaccine constructed with dual switchable nanotransformer for tumor immunotherapy

    by Zipeng Zhang, Shuang Liang, Shunli Fu, Tong Gao, Weiwei Mu, Lili Chang, Shujun Liu, Yongjun Liu, Na Zhang


  • Open Access

    Multipoint Costriking Nanodevice Eliminates Primary Tumor Cells and Associated‐Circulating Tumor Cells for Enhancing Metastasis Inhibition and Therapeutic Effect on HCC

    by Weiwei Mu, Qihui Chu, Huizhen Yang, Li Guan, Shunli Fu, Tong Gao, Xiao Sang, Zipeng Zhang, Shuang Liang, Yongjun Liu, et al.

    Eliminating primary tumor (“roots”) and inhibiting associated‐circulating tumor cells (associated‐CTCs, “seeds”) are vital issues that need to be urgently addressed in cancer therapy. Associated‐CTCs, which include single CTCs, CTC clusters, and CTC–neutrophil clusters, are essential executors in metastasis and the cause of metastasis‐related death in cancer patients. Herein, a “roots and seeds” multipoint costriking nanodevice (GV‐Lipo/sorafenib (SF)/digitoxin (DT)) is developed to eliminate primary tumors and inhibit the spread of associated‐CTCs for enhancing metastasis inhibition and the therapeutic effect on hepatocellular carcinoma (HCC). GV‐Lipo/SF/DT eliminates primary tumor cells by the action of SF, thus reducing CTC production at the roots and improving the therapeutic effect on HCC. GV‐Lipo/SF/DT inhibits associated‐CTCs effectively via the enhanced identification and capture effects of glypican‐3 and/or vascular cell adhesion molecule 1 (VCAM1) targeting, dissociating CTC clusters using DT, blocking the formation of CTC–neutrophil clusters using anti‐VCAM1 monoclonal antibody, and killing CTCs with SF. It is successfully verified that GV‐Lipo/SF/DT increases the CTC elimination efficiency in vivo, thus effectively preventing metastasis, and shows enhanced antitumor efficacy in both an H22‐bearing tumor model and orthotopic HCC models. Overall, the “roots and seeds” multipoint costriking strategy may open a new cancer treatment model for the clinic.


  • Open Access

    High-Specific Isolation and Instant Observation of Circulating Tumour Cell from HCC Patients via Glypican-3 Immunomagnetic Fluorescent Nanodevice

    by Qihui Chu, Weiwei Mu, Chuanjin Lan, Yang Liu, Tong Gao, Li Guan, Yuxiao Fang, Zipeng Zhang, Yingchao Liu, Yongjun Liu, et al.

    Purpose: Specific targeting receptors for efficiently capturing and applicable nanodevice for separating and instant observing of circulating tumour cells (CTC) are critical for early diagnosis of cancer. However, the existing CTC detection system based on epithelial cell adhesion molecule (EpCAM) was seriously limited by low expression and poor specificity of targeting receptors, and not instant observation in clinical application. Methods: Herein, an alternative glypican-3 (GPC3)-based immunomagnetic fluorescent system (C6/MMSN-GPC3) for high-specific isolation and instant observation of CTC from hepatocellular carcinoma (HCC) patients’ peripheral blood was developed. The high-specific HCC targeting receptor, GPC3, was employed for improving the sensitivity and accuracy in CTC detection. GPC3 monoclonal antibody (mAb) was linked to immunomagnetic mesoporous silica for specific targeting capture and separate CTC, and fluorescent molecule coumarin-6 (C6) was loaded for instant detection of CTC. Results: The cell recovery (%) of C6/MMSN-GPC3 increased in 106 HL-60 cells (from 49.7% to 83.0%) and in whole blood (from 42% to 80.3%) compared with MACS® Beads. In clinical samples, the C6/MMSN-GPC3 could capture more CTC in the 13 cases of HCC patients and the capture efficiency was improved by 83.3%– 350%. Meanwhile, the capture process of C6/MMSN-GPC3 was harmless, facilitating for the subsequent culture. Significantly, the C6/MMSN-GPC3 achieved the high-specific isolation and instant observation of CTC from HCC patients’ blood samples, and successfully separated CTC from one patient with early stage of HCC (Stage I) and one post-surgery patient, further indicating the potential ability of C6/MMSN-GPC3 for HCC early diagnosis and prognosis evaluation. Conclusion: Our study provides a feasible glypican-3 (GPC3)-based immunomagnetic fluorescent system (C6/MMSN-GPC3) for high-specific isolation and instant observation of HCC CTC.


  • “Layer peeling” co-delivery system for enhanced RNA interference-based tumor associated macrophages-specific chemoimmunotherapy

    by Tianqi Wang, Weiwei Mu, Feifei Li, Jing Zhang, Teng Hou, Xiuping Pang, Xiaolan Yin, Na Zhang

    RNA interference (RNAi)-based immunotherapy combined with chemotherapy has emerged as a promising therapeutic strategy for cancer treatment. The transport of siRNA and small molecular agents from the tumor vasculature to a separate therapeutic target has been impeded by multiple physiological barriers, which has restricted the development of RNAi-based chemoimmunotherapy. A nanotechnology-based co-delivery system was superior in improving the co-localization of gene and drug in the same tumor cell, while a co-delivery system for chemoimmunotherapy was expected to realize xenotype cell-targeting, which means delivering immunotherapy agents and chemotherapy drugs to immune cells and tumor cells, respectively. A multilayer structure co-delivery system was outstanding in crossing these barriers and targeting different cells in tumor tissue. Herein, a “layer peeling” co-delivery system (CDMPR) was developed with co-loaded IKKβ-siRNA and doxorubicin (DOX), in which IKKβ-siRNA was used for RNAi-based tumor associated macrophages (TAMs) polarization for immunotherapy and DOX was used for chemotherapy. A transwell assay in vitro and an immunofluorescence assay in Hepa1–6 tumor-bearing mice indicated that CDMPR exhibited a pH-sensitive disassembly ability in tumor tissue, IKKβ-siRNA was precisely delivered to M2-type TAMs and DOX was internalized into tumor cells. An M2-type TAMs polarization ability study of CDMPR demonstrated that M2-type TAMs could be polarized to M1-type TAMs by CDMPR in vitro and in vivo. In Hepa1–6 tumor-bearing mice, CDMPR exhibited improved antitumor efficiency with M2-type re-polarization ability by the precise delivery of IKKβ-siRNA and DOX to M2-type TAMs and tumor cells, respectively. Consequently, the combination of RNAi-based TAMs polarization and chemotherapy by the “layer peeling” co-delivery system would achieve an enhanced chemoimmunotherapy effect, which provides a novel strategy to improve cancer therapeutic effects.


  • Top Cited Papers
    Open Access

    A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy

    by Weiwei Mu, Qihui Chu, Yongjun Liu, Na Zhang

    Although notable progress has been made on novel cancer treatments, the overall survival rate and therapeutic effects are still unsatisfactory for cancer patients. Chemoimmunotherapy, combining chemotherapeutics and immunotherapeutic drugs, has emerged as a promising approach for cancer treatment, with the advantages of cooperating two kinds of treatment mechanism, reducing the dosage of the drug and enhancing therapeutic effect. Moreover, nano-based drug delivery system (NDDS) was applied to encapsulate chemotherapeutic agents and exhibited outstanding properties such as targeted delivery, tumor microenvironment response and site-specific release. Several nanocarriers have been approved in clinical cancer chemotherapy and showed significant improvement in therapeutic efficiency compared with traditional formulations, such as liposomes (Doxil®, Lipusu®), nanoparticles (Abraxane®) and micelles (Genexol-PM®). The applications of NDDS to chemoimmunotherapy would be a powerful strategy for future cancer treatment, which could greatly enhance the therapeutic efficacy, reduce the side effects and optimize the clinical outcomes of cancer patients. Herein, the current approaches of cancer immunotherapy and chemoimmunotherapy were discussed, and recent advances of NDDS applied for chemoimmunotherapy were further reviewed.